| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 3.64 | -0.04 (-1.09%) | 2.92 - 20.00 | 85.2 thousand (Below Avg) |
Market data as of 3:59PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 3.71 |
|---|---|
| Previous Close | 3.68 |
| Day's Range | 3.62 - 3.73 |
| Market Cap | 109.6M |
| Avg Volume (10 Day) | 147.6K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -5.13 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer
PR Newswire - Thursday 05/23/2013 8:15 AM ET
NW Bio Initiates Phase III DCVax®-L Brain Cancer Trial In Europe: King's College Hospital In The UK Is First Site To Open
PR Newswire - Thursday 05/16/2013 8:15 AM ET
Interviews Of NW Bio's CEO, On The Floor Of The New York Stock Exchange, Now Available Online
PR Newswire - Friday 05/03/2013 2:18 PM ET
Mentor Capital Cancer Immunotherapy Index Gains 28% During First Quarter of 2013
Business Wire - Thursday 05/02/2013 12:19 PM ET
| NWBO | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 8,990.00% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | 120.55 |
| Company | Last | Change |
|---|---|---|
| Oncothyreon Inc | 1.92 | -1.54% |
| Trovagene Inc | 6.89 | -0.86% |
| Biota Pharmaceuticals Inc | 3.74 | +4.76% |
| NeoStem Inc | 0.59 | +3.51% |
| Agenus Inc | 4.07 | -1.21% |
Data is delayed by at least 15 min.